Abstract:ABSTRACT Phage therapy has become one of the most promising alternatives to antibiotics as the surge of multi-drug-resistant (MDR) bacteria severely threatens global public health. The lack of a thorough understanding of pharmacokinetics (PK) and the safety study of phage has limited its clinical application. In this study, we aimed to evaluate the PK and safety of a lytic phage PA_LZ7 that infects MDR Pseudomonas aeruginosa using intravenous (IV) route in an uninfected immune-competent mice model. The active phage of PA_LZ7 exhibited an exponential decay in plasma at 2*10 8 (low dosage), 2*10 10 [medium dosage (MD)], and 2*10 11 PFU/kg [high dosage (HD)] after IV administration, and the phage titer dropped to ~4 log 10 PFU/mL over 24 h for all dosages. Phages primarily accumulated in the spleen at 1 h post-administration and gradually decreased in all dosages. The active phage titer in other organs decreased globally within 72 h as well. Plasma cytokines IL-6, IL-10, KC/GRO, and tumor necrosis factor-alpha sharply increased 1 h post-administration in mice of MD and HD groups and dropped to a normal range within 24 h. No obvious toxic effect was observed, except for the increased spleen weight and relative spleen weight in the MD and HD group and the slight lymphocytosis in the white pulp of the spleen in the HD group. In conclusion, PA_LZ7 possesses good PK properties and shows no obvious toxicity; it could be considered as a potent therapeutic candidate for the treatment of MDR P. aeruginosa infections in future phage therapy. IMPORTANCE Phage therapy is gaining traction as an alternative to antibiotics due to the rise of multi-drug-resistant (MDR) bacteria. This study assessed the pharmacokinetics and safety of PA_LZ7, a phage targeting MDR Pseudomonas aeruginosa , in mice. After intravenous administration, the phage showed an exponential decay in plasma and its concentration dropped significantly within 24 h for all dosage groups. Although there was a temporary increase in certain plasma cytokines and spleen weight at higher dosages, no significant toxicity was observed. Therefore, PA_LZ7 shows potential as an effective and safe candidate for future phage therapy against MDR P. aeruginosa infections.

Novel Lytic Phages Protect Cells and Mice against Pseudomonas aeruginosa Infection

Isolation and Characterization of Pseudomonas aeruginosa Phages with a Broad Host Spectrum from Hospital Sewage Systems and Their Therapeutic Effect in a Mouse Model.

Characterization of Phage Resistance and Phages Capable of Intestinal Decolonization of Carbapenem-Resistant Klebsiella Pneumoniae in Mice

A Novel Genus of Virulent Phage Targeting : Efficacy and Safety in a Murine Model of Pulmonary Infection

Characterization of the novel broad-spectrum lytic phage Phage_Pae01 and its antibiofilm efficacy against Pseudomonas aeruginosa

Characterization of Pseudomonas aeruginosa bacteriophages and control hemorrhagic pneumonia on a mice model

A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosa

Isolation and Characterization of Novel Phages Targeting Pathogenic <i>Klebsiella pneumoniae</i>

Characterization of a novel phage against multidrug-resistant Klebsiella pneumoniae

Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage PA_LZ7 in a mouse model

A novel virulent Litunavirus phage possesses therapeutic value against multidrug resistant Pseudomonas aeruginosa

Bacteriophages isolated from mouse feces attenuates pneumonia mice caused by Pseudomonas aeruginosa

Phage P2-71 against multi-drug resistant Proteus mirabilis: isolation, characterization, and non-antibiotic antimicrobial potential

Isolation and characterization of a multidrug-resistant Staphylococcus aureus infecting phage and its therapeutic use in mice

Two New Lytic Bacteriophages of the Myoviridae Family Against Carbapenem-Resistant Acinetobacter Baumannii

Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model Assays

Isolation and characterization of three lytic podo-bacteriophages with two receptor recognition modules against multidrug-resistant Klebsiella pneumoniae

Evaluation of the Bacteriophage MAC-1 Potential to Control Pseudomonas aeruginosa Planktonic Cells and Biofilms

Characterization of novel phage pK3-24 targeting multidrug-resistant Klebsiella pneumoniae and its therapeutic efficacy in Galleria mellonella larvae

Phage Therapy As a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter Baumannii in Mice

Characterization and genome analysis of Klebsiella phages with lytic activity against Klebsiella pneumoniae